Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00680589 · ClinicalTrials.gov registry record · Phase 1

Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response

A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target

NCT00680589: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00680589 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00680589, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

The goal of this study is to find out about the safety of injecting the gene (DNA) for mouse TYRP2 in patients with melanoma. DNA is a material that contains the information needed to produce many substances in the body. TYRP2 is a substance found in melanoma cells that helps to produce their black color. The DNA used in this study is the gene for mouse TYRP2. The gene is introduced into bacteria, which are grown in large quantities. The DNA vaccine is then made from bacteria that is inactive. We would like to see if we can immunize patients against TYRP2 by injecting mouse TYRP2 DNA. We will also follow the patients closely to see if there are any side effects. Mouse TYRP2 DNA is very similar to human TYRP2 DNA. We believe, based on lab experiments, that injection of mouse TYRP2 DNA could result in the production of immune substances (antibodies and T cells) that recognize melanoma cells. Antibodies are substances produced by your immune system to defend your body against bacteria and viruses. T cells are a type of white blood cell that can also fight infections. The small differences between mouse and human TYRP2 may allow your immune system to make the antibodies and T cells against melanoma. There is no evidence yet that injection of TYRP2 DNA results in any clinical benefit in patients.

Interventions

  • BIOLOGICAL injection of mouse TYRP2 DNA

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2006-07
Est. Completion 2011-03
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT00680589

The ClinicalTrials.gov registry entry for NCT00680589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which injection of mouse TYRP2 DNA is the first listed.

NCT00680589 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00680589 about?

NCT00680589 is a clinical study titled "Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response". The goal of this study is to find out about the safety of injecting the gene (DNA) for mouse TYRP2 in patients with melanoma. DNA is a material that contains the information needed to produce many substances in the body. TYRP2 is a substance found in melanoma cells that helps to produce their black ...

What is the current status of trial NCT00680589?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-07. Estimated completion is 2011-03.

What interventions are being tested in trial NCT00680589?

The interventions under investigation include: injection of mouse TYRP2 DNA (BIOLOGICAL).

Who is sponsoring clinical trial NCT00680589?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.